4.6 Article

Optimizing the design of invasive placebo interventions in randomized controlled trials

期刊

BRITISH JOURNAL OF SURGERY
卷 107, 期 9, 页码 1114-1122

出版社

OXFORD UNIV PRESS
DOI: 10.1002/bjs.11509

关键词

-

类别

资金

  1. NIHR Biomedical Research Centre at University Hospitals Bristol National Health Service (NHS) Foundation Trust
  2. University of Bristol
  3. MRC ConDuCT-II (Collaboration and innovation for Difficult and Complex randomised controlled Trials In Invasive procedures) Hub for Trials Methodology Research [MR/K025643/1]
  4. NIHR senior investigator award [NF-SI-0514-10114]
  5. Bristol Royal College of Surgeons Trials Centre
  6. MRC [MR/K025643/1, MC_PC_17155] Funding Source: UKRI

向作者/读者索取更多资源

Background Placebo-controlled trials play an important role in the evaluation of healthcare interventions. However, they can be challenging to design and deliver for invasive interventions, including surgery. In-depth understanding of the component parts of the treatment intervention is needed to ascertain what should, and should not, be delivered as part of the placebo. Assessment of risk to patients and strategies to ensure that the placebo effectively mimics the treatment are also required. To date, no guidance exists for the design of invasive placebo interventions. This study aimed to develop a framework to optimize the design and delivery of invasive placebo interventions in RCTs. Methods A preliminary framework was developed using published literature to: expand the scope of an existing typology, which facilitates the deconstruction of invasive interventions; and identify placebo optimization strategies. The framework was refined after consultation with key stakeholders in surgical trials, consensus methodology and medical ethics. Results The resulting DITTO framework consists of five stages: deconstruct treatment intervention into constituent components and co-interventions; identify critical surgical element(s); take out the critical element(s); think risk, feasibility and role of placebo in the trial when considering remaining components; and optimize placebo to ensure effective blinding of patients and trial personnel. Conclusion DITTO considers invasive placebo composition systematically, accounting for risk, feasibility and placebo optimization. Use of the framework can support the design of high-quality RCTs, which are needed to underpin delivery of healthcare interventions.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据